The Market Reports

Synopsis

The global market for RNAi for Therapeutic was estimated to be worth US$ 2278 million in 2024 and is forecast to a readjusted size of US$ 13125 million by 2031 with a CAGR of 27.5% during the forecast period 2025-2031.

RNA interference (RNAi) therapeutics is an advanced molecular medicine technology that utilizes double-stranded RNA molecules (such as siRNA or shRNA) to selectively silence target gene expression, thereby blocking pathogenic gene transcription or translation to achieve precise treatment of various genetic disorders, rare diseases, cancers, and viral infections. Without altering the DNA sequence, RNAi therapy offers reversible, highly specific, and low-toxicity interventions at the RNA level. Since the approval of the first RNAi drug, the field has rapidly transitioned from research to commercialization, showing immense potential in targeting the liver, nervous system, and oncology. With breakthroughs in delivery systems and expanding clinical pipelines, RNAi therapeutics is emerging as a strategic pillar in precision medicine and gene therapy industries.

The global deployment of RNAi therapeutics is accelerating, driven by multiple dimensions: breakthroughs in genomics and RNA biology have enabled higher-precision drug design; advancements in novel delivery technologies such as lipid nanoparticles (LNP) and GalNAc conjugates have significantly improved targeting efficiency to the liver and other tissues; and fast-track review policies by regulatory agencies in multiple countries have shortened the path from R&D to commercialization. Leading pharmaceutical and biotech companies are actively expanding the range of clinical indications through mergers, acquisitions, and collaborations, facilitating the market rollout of RNAi therapies in rare diseases, metabolic disorders, and cardiovascular diseases.Despite its disruptive potential, RNAi therapeutics faces technical, commercial, and regulatory hurdles. Delivery efficiency and tissue specificity remain key bottlenecks, especially in achieving effective delivery to the central nervous system and solid tumors. Additionally, RNAi molecules may trigger non-specific immune responses or off-target effects, affecting both safety and efficacy. From a business perspective, high production costs and stringent quality control standards constrain scalability and profit margins.

Intellectual property barriers and the concentration of core patents among a few leading companies further raise the technical and legal thresholds for new entrants.Demand in downstream markets is becoming increasingly segmented and diversified. Rare disease treatment, lacking effective therapies, is highly reliant on RNAi solutions, making it an early commercialization breakthrough. Cardiovascular and metabolic diseases, with their vast patient populations, offer long-term growth potential. In oncology and immunotherapy, RNAi is forming novel combination approaches with checkpoint inhibitors, CAR-T, and other treatments. With the rise of personalized medicine and companion diagnostics, RNAi therapies will become more deeply integrated into precision stratification and targeted intervention clinical pathways, driving demand toward higher efficiency, safety, and controllability.

This report aims to provide a comprehensive presentation of the global market for RNAi for Therapeutic, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of RNAi for Therapeutic by region & country, by Type, and by Application.

The RNAi for Therapeutic market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding RNAi for Therapeutic.

Market Segmentation

By Company

• Alnylam Pharmaceuticals
• Arrowhead Pharmaceuticals
• Arrowhead
• Silence Therapeutics
• Benitec Biopharma
• Phio Pharmaceuticals
• RXi Pharmaceuticals
• Arrakis Therapeutics
• Benitec Biopharma
• miRagen Therapeutics
• Sylentis
• Gradalis
• Sirnaomics
• Silenseed

Segment by Type

• siRNA
• miRNA
• shRNA

Segment by Application

• Cancer
• Cardiovascular
• HBV
• Others

Segment by Region

• North America: United States, Canada, and Mexico
• Europe: United Kingdom, Germany, France, Spain, Italy, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, and Rest of Asia Pacific
• Middle East & Africa: Saudi Arabia, South Africa, and Rest of MEA
• Latin America: Brazil, Argentina, and Rest of Latin America

*If you need a regional or country-specific version, or customized segmentation, we can tailor the report to your requirements.